It’s a terrific car if you want a great handling convertible at a low price point. As you said, it’s fun.
It’s not good at moving a lot of people or things, or going really fast, or lasting for 500k miles, or being as cheap as possible. Other cars are good at some of those things, but what is the Miata missing that is otherwise required to be a ‘good’ car?
I’m sympathetic to the intent of your argument, but man, that’s a hallava gotcha there. Other than nuclear there isn’t a compelling story for a base load source of green energy. And all the new-gen nuclear tech is a long shot for safe, cost efficient, rapid scaling right now.
I read everything. I will have AI ingest NDAs to make sure they arent glaringly weird and I then go read them, it gives me a good idea of what to look for.
It’s more that unwanted disclosure of sensitive business numbers is a product-class limitation at this time. While undoubtedly some models are better than others, expecting them not to leak information in high stakes output is unseasonable. Seems like you agree, since you are reading everything.
Jumping to another company’s offering because of one instance doesn’t seem like that’s going to meaningfully change your experience. I’m guessing there was more to it, but that’s how it came across in your first post.
I don’t see any screaming and waving arms in the parent. It’s a passionate but well reasoned and carefully presented case. If that is to be dismissed as zealotry we’ll all need to stick to writing journal papers to avoid the label.
If anything your “copyright forever” drumbeat and incorrect read of “only being trained on copyrighted works” are more hyperbolic than anything you’re responding to.
Also, the models from China are only being released open weights as competitive positioning against the globally more used competition. If the Chinese companies had a dominant market position they’d be falling prey to the same forces that have caused OpenAI and Anthropic to behave the way they do.
The proper term is a shortened form of "hear him, hear him," which was necessary because British Parliament didn't allow clapping or cheering. Instead, if you wanted to show agreement with a speaker's point, you'd shout out that everyone else should "hear" him.
Not to be confused with "hear ye," which evolved from the French "oyez," which is the imperative form of "to listen," which was shouted at a crowd before an important announcement.
Thanks, that was interesting to learn, I’d never thought about how odd the phrase sounds as-is.
There’s a fascinating complexity to what constitutes constructive feedback, criticism, or dismissal. And to when it’s okay to provide one, the other, or none at all.
A new bug appears, it’s in an encryption layer. You solve this by deciding to disable the encryption layer because user experience is better without the errors. You write it up as a recruitment piece for your engineering team.
There may be some good answers and lessons, but they didn’t make it into the article. Saying it’s on a cloud provider’s private network so encryption between your nodes isn’t necessary is a bold choice. Also, what happened to the root cause? Why did it start failing a week ago? Was a downgrade of the offending code not possible?
Not all bug investigations are worth really digging into. Sometimes the right call is to find any fix and move on. But all the nuance, judgement, implications, and lessons learned failed to make it into this post. And they are what make reading incident reports interesting for most engineers.
As pointed out in the article, naproxen is an NSAID like Ibuprofen, though slightly more COX1 selective. It likely has a somewhat lower risk of serious renal and cardiovascular events, but higher risk of GI bleeds. There are some studies that show little to no increase cardiovascular risk, but most do show some or even comparable to ibuprofen.
Convenience vs ibuprofen is a thing given the longer half life, but it still generally comes with similar risks. If you are taking anything for more than just an occasional headache, definitely discuss with a doctor, COX2 selectives like celecoxib may be a better risk profile and even more convenient.
(COX1 and COX2 selectivity loosely separate which systems get the brunt of the side effects)
I weirdly always found Naproxen much more effective than ibuprofen but also find Celebrex great which seems to further confuse the whole COX 1 vs 2 situation
Recently, I've had to take Celebrex (celecoxib) for a back injury and I've been taking it longer than is normally recommended—and that truly worries me (I've determined I have to come off it ASAP).
Where I am (Australia), most doctor's prescriptions that have to be taken long-term are issued as the first script plus five repeats. Not so with Celebrex, a script can only be dispensed three times (3 x pk of 30 200mg capsules — one per day, for 90 days max) and scripts can only be dispensed every 21 days. Reason: Celebrex is only recommended for short-term use because it's considered a dangerous drug with possible irreversible side effects if taken for too long.
This was not news to me even before taking Celebrex, way back in the 1990s I was prescribed its sister drug called Vioxx (rofecoxib) for back pain and it was much more effective than Celebrex (at least it was for me).
Anyway, sometime around 2000 I read an article in the journal Science about a significant statistical increase in deaths by heart attack, stroke etc. by those talking rofecoxib. At the time I said to myself it won't be long before Vioxx is banned. It took another three to four years for that to happen as Merck Pharmaceuticals fought the decision every inch of the way. It's worth reading the Wiki about this (when it's between a drug company and millions of dollars profit patients come off second best):
What's relevant here is that the related drug Celebrex survived because its side effects—whilst manifestly similar—aren't quite as bad as Vioxx. In short, Celebrex's COX-2 selectivity versus other less selective NSAIDs like aspirin (which target both COX-1 and COX-2) was deemed sufficiently beneficial despite its potential serious side effects.
Note: I'm not offering medical advice here and you should always take that from your medical practitioner. I mention this because only several days ago I had a discussion with two younger doctors who'd never heard of Vioxx let alone the Vioxx/Celebrex controversy.
You may be interested in this YouTube video on Vioxx. Unfortunately it's over hyped and designed to alarm but it's essentially factually correct: https://m.youtube.com/watch?v=K0GrFnOpJoU
The higher risk of GI bleeds is could be somewhat balanced by not having to take as many.
There are also slow release forms of naproxen. (Which make sense given its long action: lets people fade in the next one while the previous dose slowly fades out). That could also help make it easier on the GI tract.
> The higher risk of GI bleeds is somewhat balanced by not having to take as many!
Unless I am missing something, the data really doesn't back that up. naproxen is much more longer lasting and has a higher chance of causing ulcers. Hence why its not over the counter in the UK and is prescribed with omeprazole to reduce the risk of issues.
I'm reading about this in more detail. Indeed, it's not the contact between the medication and the digestive tract that is the problem, but simply its presence in the blood stream. By inhibiting those certain enzymes, it reduces the production of prostaglandings, causes problems for the lining.
Naproxen will be around longer due to its long half-life, so it creates more opportunity for this problem.
Neither WebRTC or WebGL are remotely ‘useless’. Very fair though to say that you would prefer to have them disabled and/or whitelisted for certain sites.
Calling the industry largely a scam is pretty strong. Of course for the small minority of technically competent people with interest and time it will always be cheaper to do something yourself rather than pay a business to accomplish the same thing. But most people cannot/do not want to do it themselves, and regulations are there at least partially to help protect them against the house-fire-waiting-to-happen untrained handyman.
Sure a bunch of businesses opportunistically up-charge, some I'm sure are predatory, and there are obviously efficiencies to improve, but overall scam it is not.
It’s a terrific car if you want a great handling convertible at a low price point. As you said, it’s fun.
It’s not good at moving a lot of people or things, or going really fast, or lasting for 500k miles, or being as cheap as possible. Other cars are good at some of those things, but what is the Miata missing that is otherwise required to be a ‘good’ car?
reply